Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
BPMC

BPMC - Blueprint Medicines Corp Stock Price, Fair Value and News

$129.46 
Market Closed as of 18 Jul 2025, 04:00 pm ET

BPMC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BPMC Price Action

BPMC RSI Chart

BPMC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BPMC Valuation

BPMC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BPMC Fundamentals

BPMC Revenue

BPMC Earnings

BPMC Profitability

BPMC Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025562.1M000
2024282.2M362.8M434.4M508.8M
2023204.6M225.6M216.2M249.4M
2022221.2M230.5M272.3M204.0M
2021640.3M486.9M333.5M180.1M
202071.9M312.5M553.1M793.7M
201950.0M55.5M61.0M66.5M
201827.2M33.0M38.7M44.5M
201726.8M25.6M27.5M21.4M
201617.6M22.0M24.7M27.8M
201500011.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Blueprint Medicines Corp

BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEblueprintmedicines.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES660